Introduction
============

Undifferentiated embryonal sarcoma of the liver (UESL) is an aggressive disease that accounts for \<0.2% of all primary liver tumors ([@b1-ol-0-0-11963]). UESL was first described as a mesenchymoma by Donovan and Santulli ([@b2-ol-0-0-11963]) in 1946, and was subsequently termed malignant mesenchymoma by Stout ([@b3-ol-0-0-11963]) in 1948 before being first recognized as a distinct form of sarcoma by Stocker and Ishak ([@b4-ol-0-0-11963]) in 1978.

UESL predominantly develops in the childhood, with a peak incidence between 6 and 10 years of age ([@b4-ol-0-0-11963]); however, it also occasionally occurs in adults ([@b5-ol-0-0-11963]). UESL usually manifests with nonspecific clinical presentations and preoperative examination results ([@b3-ol-0-0-11963]--[@b5-ol-0-0-11963]). The majority of the relevant studies involve pediatric cases and have reported a poor prognosis, even in patients who undergo complete surgical resection of the tumor ([@b4-ol-0-0-11963],[@b5-ol-0-0-11963]). However, patient prognosis has recently been improved using therapeutic strategies combining surgery with chemotherapy, especially with neoadjuvant chemotherapy.

UESL in adults is extremely rare; to the best of our knowledge, the currently available literature includes only 108 reported cases of UESL in adult patients. Due to the low incidence of UESL, especially among adults, the majority of the literature comprises case reports, with a limited number of small case series. Therefore, limited data are available regarding the prognosis of adults patients with UESL, especially in terms of 1-, 3- and 5-year survival rates. The effects of chemotherapy or neoadjuvant chemotherapy on UESL in the adult population also remain unclear. To improve the prognosis of these patients, more cases and treatment experiences should be reported.

The present study aimed to analyze a single-institution retrospective case series of UESL in adults, which was one of the largest reported series to date and included the first report of overall survival in this population, as well as to perform a systematic review of the literature to investigate the presentation, treatment modalities and outcomes of this rare tumor.

Materials and methods
=====================

### Retrospective analysis

A retrospective review was conducted of three cases of UELS in patients \>15 years of age treated at the Center of Hepatopancreatobiliary Diseases of Beijing Tsinghua Changgung Hospital between 2015 and 2018. The recorded data included the demographic (age and sex) and clinical characteristics of the patients, including the year of diagnosis, signs and symptoms at presentation, laboratory data, imaging results, tumor extension, type of surgery, tumor size, pathology reports, use of chemotherapy and interventional therapy, presence and location of recurrence, and the duration of overall survival in months. These results are presented as a descriptive analysis of a case series.

### Systematic review

A systematic review of the available literature was performed using MEDLINE, Web of Science, Embase, the Google Scholar database and the Cochrane Library to search for all published studies regarding UELS. The PRISMA guidelines were followed (<http://www.prisma-statement.org/>). The search terms were 'undifferentiated embryonal sarcoma' and 'adult'. The inclusion criteria were as follows: English or Chinese language, human studies, adult patients (≥15 years), full-text availability and completeness of clinical data. Studies lacking primary data were excluded, but were examined to identify any relevant citations. Data extraction from relevant studies was performed to search for additional studies. The search was independently performed by two authors, and disagreements regarding study inclusion were resolved through discussion among all authors. The aforementioned clinical parameters from the cases in the included studies were evaluated.

### Statistical analysis

Statistical analyses and graphing were performed using GraphPad Prism 7.0 software (GraphPad Software, Inc.). Survival was estimated using the Kaplan-Meier method, and the results were compared using the two-sided log-rank test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Retrospective analysis of a case series

#### Demographic and clinical characteristics

As presented in [Table I](#tI-ol-0-0-11963){ref-type="table"}, the three adult patients with UELS were female, with a mean age of 21 years at diagnosis (range, 15--25 years). Symptoms upon admission included fever, chills, nausea, vomiting and weight loss (patient A), and abdominal pain and mass (patients B and C). Laboratory analysis revealed elevated levels of alkaline phosphatase (ALP, patient A), activated partial thromboplastin time/prothrombin time (patients B and C), aspartate aminotransferase, alanine aminotransferase, direct bilirubin, ALP and γ-glutamyl transpeptidase (patient C), as well as decreased albumin, red blood cell count, hemoglobin and red blood cell-specific volume (patient C). Tumor marker levels were normal in patients A and C, whereas the level of protein induced by vitamin K absence or antagonist-II (PIVKA-II) was elevated outside of the normal range in patient C. In all patients, ultrasound examination and computed tomography revealed a cystic and solid mass.

#### Treatment and outcome

[Table II](#tII-ol-0-0-11963){ref-type="table"} summarizes the treatments and outcomes of the three patients. One patient was admitted to the hospital for recurrent UESL. The lesions involved the right lobe in two cases and the left lobe in one case. One patient had undergone biopsy and neoadjuvant chemotherapy (vincristine, cytoxan and cis-platinum) prior to admission. Two patients received preoperative transarterial chemoembolization. Surgical treatment involved right trisectionectomy in two cases, and extended left hemihepatectomy in one case. Two patients received postoperative chemotherapy (dacarbazine plus lobaplatin or doxorubicin, ifosfamide, mesna and dacarbazine). One patient underwent postoperative hepatic artery infusion chemotherapy.

Two patients experienced recurrence, with one in the lung and the other in the lung plus inguinal lymph nodes. Two patients are currently alive after follow-up, one after 9 months of follow-up and the other after 41 months of follow-up. One patient succumbed to pulmonary recurrence at 17 months.

#### Pathological characteristics

In one case, the tumor size was \<10 cm; in the other two cases, the tumor size was \>20 cm. The tumor in one case exhibited visible capsule infiltration and tumor thrombus (portal vein and hepatic vein). Immunohistochemical results revealed expression of the cytokeratin antibody AE1/AE3, the melanoma antibody HMB45 and DESMIN in one case; vimentin, CD31 and periodic acid-schiff stain (PAS) positive in two cases; and CD34 and smooth muscle actin in all three cases. The rate of Ki-67 expression was \>60% in all cases. The results are presented in [Table III](#tIII-ol-0-0-11963){ref-type="table"}.

### Systematic literature review

#### Demographic data

The literature search identified 108 reported adult cases of UESL. Of these cases, 75 were reported and summarized by Pachera *et al* ([@b6-ol-0-0-11963]) and Chen *et al* ([@b7-ol-0-0-11963]) between 1955 and 2011. An additional 33 cases were reported between 2011 and 2019 ([Table IV](#tIV-ol-0-0-11963){ref-type="table"}) ([@b8-ol-0-0-11963]--[@b36-ol-0-0-11963]). Thus, including the present case series, a total of 111 adult cases of UESL have been reported to date. Among all cases, the median age was 29 years (range, 15--86 years), and the peak incidence was between the ages of 15 and 24 years ([Fig. 1](#f1-ol-0-0-11963){ref-type="fig"}). Sex was reported for 107 patients; of these, 44 (41%) were men and 63 (59%) were women, with a male: Female ratio of 1:1.4 ([Table IV](#tIV-ol-0-0-11963){ref-type="table"}).

#### Treatment and outcome

Complete treatment and survival data were available for 83 patients. Among these patients, the median follow-up was 18 months (range, 2 days to 204 months), and median survival was 48 months (range, 2 days to 204 months). Among all the 83 patients, the 1-, 3- and 5-year overall survival rates were 72, 56 and 47%, respectively ([Fig. 2A](#f2-ol-0-0-11963){ref-type="fig"}), and the 1-, 3- and 5-year disease-free survival rates were 67, 40 and 35%, respectively ([Fig. 2B](#f2-ol-0-0-11963){ref-type="fig"}).

Patients who underwent complete tumor resection with adjuvant and/or neoadjuvant chemotherapy exhibited significantly higher survival rates compared with those in patients who underwent surgery alone. For patients treated with chemotherapy plus surgery vs. surgery alone, the overall survival rates were as follows: 1-year, 93% vs. 65%; 3-year, 80% vs. 40%; and 5-year, 63% vs. 34% (P=0.0040; [Fig. 3A](#f3-ol-0-0-11963){ref-type="fig"}). The corresponding disease-free survival rates were as follows: 1-year, 86% vs. 47%; 3-year, 58% vs. 19%; and 5-year, 58% vs. 13% (P=0.0001; [Fig. 3B](#f3-ol-0-0-11963){ref-type="fig"}).

Discussion
==========

In the present study, one of largest case series of adult UESL to date was analyzed. The literature review confirmed that a higher survival rate was associated with treatment strategies combining complete tumor resection and chemotherapy compared with radical tumor resection alone. To the best of our knowledge, 111 adult cases of UESL have been reported to date, including the present case series. The present analysis is the first to include a thorough 1-, 3- and 5-year survival rate analysis in this population.

UESL is rare and usually occurs in children; its incidence decreases with increasing age, with peak incidence occurring between the ages of 6 and 10 years ([@b3-ol-0-0-11963],[@b5-ol-0-0-11963]). Among adult patients, the present study identified another peak between the ages of 15 and 24 years. It is possible that UESL is similar to embryonal tumors, and thus may predominantly occur in young adults. In addition, a female preponderance was observed in the present systematic review, with a male: Female ratio of 1:1.4. In the present case series, all three patients were female, and the median age at diagnosis was 21 years (range, 15--25 years).

UESL exhibits a nonspecific clinical presentation. The most common symptoms are right upper quadrant abdominal pain and mass. Other symptoms include vomiting, diarrhea, weight loss, fever, and jaundice ([@b3-ol-0-0-11963],[@b6-ol-0-0-11963],[@b7-ol-0-0-11963]). Among the cases included in the present retrospective analysis, the symptoms upon admission were fever, chills, nausea, vomiting and weight loss in one patient, and abdominal pain and mass in the other two patients. Laboratory findings, including liver function and tumor markers, are usually normal at the time of UESL presentation ([@b6-ol-0-0-11963],[@b7-ol-0-0-11963]). Among the present cases, one patient exhibited obviously altered liver function, and tumor markers, including α-fetoprotein, carcinoembryonic antigen, carbohydrate antigen (CA)199 and CA125, were negative in all patients. Only one of the three patients exhibited elevated PIVKA-II. In the ultrasound examination and CT scans, UESL often presents as a large solid or cystic mass, with enhancement in the solid parts ([@b33-ol-0-0-11963],[@b37-ol-0-0-11963]). This is similar to the cases in the present study.

From its first recognition as a unique clinicopathologic entity in 1978 until the early 1990s, UESL has been associated with a poor prognosis, even in patients who underwent complete surgical resection of the tumor ([@b1-ol-0-0-11963],[@b2-ol-0-0-11963],[@b37-ol-0-0-11963]). Due to its low incidence, especially among adults, UESL survival data are mainly from case reports or small case series of childhood patients. In the initial report by Stocker and Ishak ([@b4-ol-0-0-11963]), the median survival was \<1 year, and only 19% (6/31) of the reported patients were alive and disease-free after resection for the median follow-up of 9 months (range, 2--52 months). Among the 40 patients reported in the literature between 1950 and 1988, 47.5% died after a mean duration of 11.9 months, 15.0% survived with disease, and 37.5% were alive and disease-free (average, 37.5 months) ([@b38-ol-0-0-11963]).

In the recent two decades, an increasing number of long-term survivors have been reported. These cases have mainly included children who underwent surgical tumor resection, especially with postoperative chemotherapy ([@b39-ol-0-0-11963]--[@b42-ol-0-0-11963]). In a review of 68 adult patients between 1995 and 2007, Lenze *et al* ([@b5-ol-0-0-11963]) observed a median survival of 29 months among all patients, and that patients who underwent complete tumor resection followed by adjuvant chemotherapy exhibited significantly improved survival compared with that of patients who underwent surgery alone. Similarly, the present results demonstrated significantly improved survival among patients treated with complete tumor resection plus adjuvant and/or neoadjuvant chemotherapy compared with patients treated with surgery alone. In addition, in pediatric cases, neoadjuvant chemotherapy can reduce the tumor size and stage, making complete surgical resection possible ([@b25-ol-0-0-11963],[@b42-ol-0-0-11963],[@b43-ol-0-0-11963]). However, due to insufficient data, the effect of neoadjuvant chemotherapy in adult patients with UESL and its influence on survival cannot be currently assessed.

The present findings were limited by the retrospective study design and the low number of cases. The rarity of UESL, especially in adults, precludes large prospective single-institution studies. In addition, the effects of neoadjuvant treatment of UESL could not be evaluated in this study due to the limited relevant data in adult patients. However, this may be confirmed as a useful method in the future, based on the results of studies on pediatric UESL.

In conclusion, the present study reports one of largest case series of adult UESL to date. The results of our systematic literature review were the first to report the survival rates, which confirmed significantly improved survival following treatment with complete tumor resection plus chemotherapy compared with radical tumor resection alone. In the future, multi-institutional or global collaborative studies may represent the best approach to investigating adult UESL and standardizing its treatment.
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###### 

Demographic and clinical characteristics of the patients with undifferentiated embryonal sarcoma of the liver in the retrospective case series.

  No.                                               Age, years   Sex   Symptoms                                      Laboratory test results                                    Tumor markers   US findings             CT findings
  ------------------------------------------------- ------------ ----- --------------------------------------------- ---------------------------------------------------------- --------------- ----------------------- --------------------------------------
  A                                                 15           F     Fever, chill, nausea, vomiting, weight loss   ↑ALP                                                       Normal          N.A.                    Cystic and solid mass
  B                                                 24           F     Abdominal pain and mass                       ↑PT, APTT                                                  Normal          Cystic and solid mass   Mass with enhancement in solid parts
  C^[a](#tfn1-ol-0-0-11963){ref-type="table-fn"}^   25           F     Abdominal pain and mass                       ↑PT, APTT, AST, ALT, DBIL, ALP, GGT; ↓ALB, RBC, HGB, HCT   ↑PIVKA-II       N.A.                    Lobulated low enhancement mass

Patient C was admitted to hospital for recurrent UESL 2 months after initial surgery. ALP, alkaline phosphatase; GGT, γ-glutamyl transpeptidase; PT, prothrombin time; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; ALT, alanine aminotransferase; DBIL, direct bilirubin; ALB, albumin; RBC, red blood cell count; HGB, hemoglobin; HCT, hematocrit value; PIVKA-II, protein induced by vitamin K absence-II; F, female; N.A., not available; US, ultrasound.

###### 

Treatment and outcome of the patients with undifferentiated embryonal sarcoma of the liver in the retrospective case series.

  No.   Year of diagnosis   Tumor extension                                       Biopsy   Treatment before surgery   Type of surgery                 Treatment after surgery          Recurrence          Outcome   OS, months
  ----- ------------------- ----------------------------------------------------- -------- -------------------------- ------------------------------- -------------------------------- ------------------- --------- ------------
  A     2016                R + L                                                 \+       VCR + CTX + PDD; TACE      Right trisectionectomy          --                               No                  Alive     41
  B     2017                L                                                     --       --                         Extended left hemihepatectomy   DTIC + LBP; HAIC (EPI + L-OHP)   Lung                Dead      17
  C     2018                R + L^[a](#tfn2-ol-0-0-11963){ref-type="table-fn"}^   --       TACE                       Right trisectionectomy          AIM, AIDM                        Lung, inguinal LN   Alive     9

Patient C was admitted to hospital for recurrent UESL 2 months after initial surgery. VCR, vincristine; CTX, cytoxan; PDD, cis-platinum; TACE, transarterial chemoembolization; OS, overall survival; DTIC, dacarbazine; LBP, lobaplatin; HAIC, hepatic artery infusion chemotherapy; EPI, epirubicin; L-OHP, oxaliplatin; AIM, doxorubicin, ifosfamide and mesna; AIDM, doxorubicin, ifosfamide, mesna and dacarbazine; LN, lymph node.

###### 

Pathological characteristics of the patients with undifferentiated embryonal sarcoma of the liver in the retrospective case series.

  No.   Size, cm     Infiltration of capsule   Tumor thrombus   Necrosis, %   AE1/AE3   Vimentin   HMB45   CD31   CD34   KI-67   SMA   DESMIN   PAS
  ----- ------------ ------------------------- ---------------- ------------- --------- ---------- ------- ------ ------ ------- ----- -------- ------
  A     9×7×8        --                        --               100           N.A.      N.A.       N.A.    \+     \+     70%+    \+    \+       N.A.
  B     20×15×12.5   \+                        \+               N.A.          \+        \+         N.A.    N.A.   \+     60%+    \+    --       \+
  C     22×19×10     --                        --               N.A.          --        \+         \+      \+     \+     60%+    \+    --       \+

AE1/AE3, cytokeratin antibody; HMB45, melanoma antibody; SMA, smooth muscle actin; PAS, periodic acid-schiff stain; DESMIN, a protein marker of muscle; N.A., not available.

###### 

New cases of undifferentiated embryonal sarcoma of the liver between 2011 and 2019 in the literature.

  Author, year                 Age, years   Sex   Site                                                Biopsy   Treatment before surgery   Surgery                          Treatment after surgery             Recurrence (treatment)                                                                    Outcome             OS, mos   (Refs.)
  ---------------------------- ------------ ----- --------------------------------------------------- -------- -------------------------- -------------------------------- ----------------------------------- ----------------------------------------------------------------------------------------- ------------------- --------- -----------------------
  Gerson *et al*, 2019         71           M     L                                                   --       --                         Left lobectomy                   --                                  N.A.                                                                                      N.A.                N.A.      ([@b8-ol-0-0-11963])
  Capozza *et al*, 2019        20           F     R^[c](#tfn6-ol-0-0-11963){ref-type="table-fn"}^     --       --                         Right hepatectomy                VAIA                                No                                                                                        Alive               177       ([@b9-ol-0-0-11963])
  Capozza *et al*, 2019        17           M     R                                                   \+       --                         Right hepatectomy                IFO + VCR + ACTD                    No                                                                                        Alive               20        ([@b9-ol-0-0-11963])
  Esteban *et al*, 2018        53           F     R^[a](#tfn4-ol-0-0-11963){ref-type="table-fn"}^     \+       Radiotherapy               Not performed                    --                                  --                                                                                        DOD                 N.A.      ([@b10-ol-0-0-11963])
  Esteban *et al*, 2018        35           F     R+L                                                 --       --                         Extended right hepatectomy       --                                  LR in 24 mos (ADR+IFO)                                                                    Alive               60        ([@b10-ol-0-0-11963])
  Pandit *et al*, 2019         34           M     R+L^[b](#tfn5-ol-0-0-11963){ref-type="table-fn"}^   --       --                         Mass enucleation                 --                                  No                                                                                        Alive               6         ([@b11-ol-0-0-11963])
  Pandit *et al*, 2019         29           F     R                                                   \+       --                         Radical resection                --                                  LR, peritonea in 4 mos                                                                    DOD                 8         ([@b12-ol-0-0-11963])
  Pinamonti *et al*, 2018      60           F     R                                                   --       --                         Segmentectomy                    VCR + ACTD + CTX                    No                                                                                        Alive               30        ([@b13-ol-0-0-11963])
  Beksac *et al*, 2018         26           F     L                                                   \+       --                         Nonanatomic resection            PTX + CDDP + IFO                    No                                                                                        Alive               72        ([@b14-ol-0-0-11963])
  Khan *et al*, 2017           21           M     R                                                   \+       IFO + ADR                  LTx                              --                                  No                                                                                        Alive               18        ([@b15-ol-0-0-11963])
  Mori *et al*, 2017           65           F     R+L                                                 --       --                         Right trisectionectomy           --                                  LR in 18 mos (resection)                                                                  Alive               26        ([@b16-ol-0-0-11963])
  Lee *et al*, 2016            51           M     R                                                   --       --                         Right hemihepatectomy            --                                  N.A.                                                                                      N.A.                N.A.      ([@b17-ol-0-0-11963])
  Giakoustidis *et al*, 2016   29           F     R+L                                                 \+       PVE                        Right trisectionectomy           CTX + CDDP + ADR                    1st LR in 12 mos (CTX + CDDP + ADR), 2nd LR and spine metastasis                          DOD                 28        ([@b18-ol-0-0-11963])
  Treitl *et al*, 2016         30           M     L                                                   \+       --                         Left hepatectomy                 ADR + IFO                           No                                                                                        Alive               3         ([@b19-ol-0-0-11963])
  Zanwar *et al*, 2017         20           M     R                                                   \+       IVA                        Right hepatectomy                IVA                                 No                                                                                        Alive               24        ([@b20-ol-0-0-11963])
  Masuda *et al*, 2015         52           F     R+L                                                 --       --                         Right trisectionectomy           --                                  LR in 12/19/25/35/42/47 mos (resections and RFA); bone metastases and TT in azygos vein   DOD                 62        ([@b21-ol-0-0-11963])
  Masuda *et al*, 2015         53           F     L+R                                                 --       --                         Extended left hepatectomy        --                                  LR in 4/14 mos (resections and RFA)                                                       Alive               65        ([@b21-ol-0-0-11963])
  Kallam *et al*, 2015         47           M     L                                                   --       --                         Left lobectomy (R1)              --                                  Lung metastases in 2 mos (ADR+ IFO, GEM+ DXT)                                             Death (pneumonia)   8         ([@b22-ol-0-0-11963])
  Xie *et al*, 2014            39           M     R                                                   \+       --                         Tumor resection                  --                                  LR in 2 mos                                                                               Alive               2         ([@b23-ol-0-0-11963])
  Cao *et al*, 2014            37           M     L                                                   --       --                         Lobectomy                        --                                  LR in 19 mos (TACE); Lung and mediastinum LN metastasis in 24 mos                         DOD                 34        ([@b24-ol-0-0-11963])
  Cao *et al*, 2014            24           F     R                                                   --       --                         Lobectomy                        MAID                                LR in 4 mos (N.A.)                                                                        Alive               24        ([@b24-ol-0-0-11963])
  Hanafiah *et al*, 2014       20           M     R+L                                                 \+       --                         Extended right hepatectomy       --                                  LR in 6 mos (ADM)                                                                         Alive               6         ([@b25-ol-0-0-11963])
  Hong *et al*, 2014           67           M     R                                                   --       --                         Segmentectomy                    --                                  LR in 6 mos (MAID)                                                                        Death (sepsis)      8         ([@b26-ol-0-0-11963])
  Ismail *et al*, 2013         16           F     R+L                                                 \+       CAV/ETIF/IF + ADR          Right extended hemihepatectomy   IVADO, VP-16/CDDP, VRB/CTX          No                                                                                        Alive               50        ([@b27-ol-0-0-11963])
  Jia *et al*, 2013            46           F     R                                                   --       --                         Segmentectomy                    --                                  LR in 6 mos                                                                               DOD                 12        ([@b28-ol-0-0-11963])
  Hu *et al*, 2012             19           F     R                                                   --       --                         Right hemihepatectomy            --                                  No                                                                                        Alive               40        ([@b29-ol-0-0-11963])
  Varol *et al*, 2012          33           F     L                                                   \+       --                         Not performed                    --                                  --                                                                                        DOD                 N.A.      ([@b30-ol-0-0-11963])
  Dhanasekaran *et al*, 2012   54           M     L                                                   \+       ADR+ IFO, DTIC; TACE       LTx                              --                                  No                                                                                        Alive               167       ([@b31-ol-0-0-11963])
  Lightfoot *et al*, 2012      78           F     R                                                   --       --                         Partial right hepatectomy        --                                  No                                                                                        Alive               6         ([@b32-ol-0-0-11963])
  Noguchi *et al*, 2012        27           F     R                                                   --       --                         Right trisectionectomy           VADRCA+ CDDP, MCVC; radiotheraphy   No                                                                                        Alive               60        ([@b33-ol-0-0-11963])
  Tanaka *et al*, 2012         51           F     R                                                   --       --                         Segmentectomy                    --                                  LR, lung and spine metastasis in 48 mos                                                   DOD                 60        ([@b34-ol-0-0-11963])
  Tucker *et al*, 2012         74           F     L                                                   --       --                         Left hepatectomy                 --                                  No                                                                                        Alive               9         ([@b35-ol-0-0-11963])
  Kim *et al*, 2011            47           F     L                                                   --       --                         Left lateral sectionectomy       MAID                                Lumbar spine in 2 years (radiotheraphy)                                                   DOD                 48        ([@b36-ol-0-0-11963])

Multifocal, with metastasis in left auricular and right costal arch.

Tumor ruptured prior to surgery, with thrombus in the right atrium.

Tumor ruptured prior to surgery. CDDP, cisplatin; PTX, taxol; ADR, adriamycin; IFO, ifosfamide; DTIC, dacarbazine; ACTD, actinomycin D; CTX, cyclophosphamide; VCR, vincristine; GEM, gemcitabine; DXT, docetaxel; VRB, vinorelbina; VP-16, etoposide; MAID, mesna, doxorubicin, ifosfamide and dacarbazine; VADRCA, vincristine, adriamycin, cyclophosphamide and actinomycin D; CAV, cyclophosphamide, adriamycin and vincristine; MCVC, ranimustine, carboplatin, etoposide and cyclophosphamide; IVA, ifosfamide, vincristine and adriamycin; IVADO, ifosfamide, vincristine, actinomycin D and adriamycin; ETIF, epirubicin, taxotere, irinotecan and 5-fluorourcil; IF, irinotecan and 5-fluorourcil; LTx, liver transplantation; LR, local recurrence; PVE, portal vein embolization; TT, tumor thrombosis; LN, lymph node; DOD, died of disease; N.A., not available; mos, months.
